PerkinElmer divests Illumination and Detection Solutions business

PerkinElmer, Inc. (NYSE: PKI), a global leader focused on improving the health and safety of people and the environment, today announced that it has agreed to sell its Illumination and Detection Solutions (IDS) business to Veritas Capital Fund III, L.P., a New York-based private equity firm, for approximately $500 million in cash ($482 million net of payment for acquired cash balances).

“In addition, this transaction should reduce the company's exposure to more cyclical end markets and improve our top-line growth profile. Furthermore, we would expect adjusted gross margins to improve by over 200 basis points, contributing to higher earnings growth.”

IDS includes approximately 3,000 employees and 14 manufacturing facilities worldwide and is a leading global provider of custom-designed specialty lighting and sensor components, subsystems and integrated solutions to major OEMs serving a number of applications within various health, environmental, and security segments. The business is expected to generate revenue of approximately $300 million in 2010.

"The divestiture of our IDS business reduces the complexity of the company and frees up capital to reinvest in our more attractive Human Health and Environmental Health end markets," said Robert Friel, chairman and CEO of PerkinElmer. "In addition, this transaction should reduce the company's exposure to more cyclical end markets and improve our top-line growth profile. Furthermore, we would expect adjusted gross margins to improve by over 200 basis points, contributing to higher earnings growth."

As a result of the agreement to sell IDS, the Company will report the financial results for IDS as a discontinued operation. Consequently, for the third quarter 2010, the Company forecasts organic revenue to grow at a high single digit rate and now forecasts GAAP earnings per share from continuing operations in the range of $0.19 to $0.21. On a non-GAAP basis, which includes the adjustments noted in the attached reconciliation, the Company now forecasts adjusted earnings per share from continuing operations in the range of $0.27 to $0.29.

For the full year 2010, the Company forecasts organic revenue to grow at a high single digit rate and now forecasts GAAP earnings per share from continuing operations in the range of $1.06 to $1.11. On a non-GAAP basis, which includes the adjustments noted in the attached reconciliation, the Company now forecasts adjusted earnings per share from continuing operations in the range of $1.24 to $1.29.

Although the Company has not issued guidance for 2011, the Company expects that the transaction will be $0.08 to $0.10 dilutive in 2011 or 5%-6% based on the current 2011 Thomson First Call consensus of $1.70.

The Company also announced today that its Board of Directors has authorized an increase in the number of shares of the Company's common stock available for repurchase to 13 million. Purchases will be made through open market transactions or privately negotiated transactions, subject to market conditions and trading restrictions.

The transaction is expected to close by the end of 2010 and is subject to customary closing conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

Source:

 PerkinElmer, Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    PerkinElmer. (2019, June 17). PerkinElmer divests Illumination and Detection Solutions business. News-Medical. Retrieved on August 24, 2019 from https://www.news-medical.net/news/20100902/PerkinElmer-divests-Illumination-and-Detection-Solutions-business.aspx.

  • MLA

    PerkinElmer. "PerkinElmer divests Illumination and Detection Solutions business". News-Medical. 24 August 2019. <https://www.news-medical.net/news/20100902/PerkinElmer-divests-Illumination-and-Detection-Solutions-business.aspx>.

  • Chicago

    PerkinElmer. "PerkinElmer divests Illumination and Detection Solutions business". News-Medical. https://www.news-medical.net/news/20100902/PerkinElmer-divests-Illumination-and-Detection-Solutions-business.aspx. (accessed August 24, 2019).

  • Harvard

    PerkinElmer. 2019. PerkinElmer divests Illumination and Detection Solutions business. News-Medical, viewed 24 August 2019, https://www.news-medical.net/news/20100902/PerkinElmer-divests-Illumination-and-Detection-Solutions-business.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
New PerkinElmer assay kits use AlphaLISA technology for biotherapeutic drug development